



GAU-1644

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

p#6

In Re the Application of: )

IRVIN )

Serial No.: 09/945,250 ✓ )

Filed: August 31, 2001 )

Atty. File No.: 2879-84 )

For: "METHOD FOR TREATMENT OF )  
INFLAMMATORY DISEASE" )INFORMATION DISCLOSURE  
STATEMENT

## CERTIFICATE OF MAILING

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS  
BEING DEPOSITED WITH THE UNITED STATES POSTAL  
SERVICE AS FIRST CLASS MAIL IN AN ENVELOPE  
ADDRESSED TO THE ASSISTANT COMMISSIONER FOR  
PATENTS, WASHINGTON, DC 20231 ON 8/21/02  
SHERIDAN ROSS P.C.BY: Angela K. DallasCommissioner of Patents  
Washington, D.C. 20231

Dear Sir:

Pursuant to Applicant's duty of disclosure under 37 CFR § 1.56 and 37 CFR §§ 1.97-1.98, Applicant hereby provides a copy of each of the documents identified on the enclosed PTO Form 1449, although Applicant does not admit that any of such documents, alone or in any combination, are considered to be material to patentability as defined in 37 CFR § 1.56(b). Moreover, the inclusion of these documents is not to be construed as an admission by Applicant that each such document is prior art as to the above-identified patent application.

RECEIVED

AUG 28 2002

Respectfully submitted,

SHERIDAN ROSS P.C.

TECH CENTER 1600/2900

By: Angela K. DallasAngela K. Dallas  
Registration No. 42,460  
1560 Broadway, Suite 1200  
Denver, CO 80202-5141  
(303) 863-9700Date: August 21, 2002

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
2879-84SERIAL NO.  
09/945,250INFORMATION DISCLOSURE STATEMENT  
(Use several sheets if necessary)APPLICANT  
IRVINFILING DATE  
August 31, 2001

GROUP ART

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROP.
	1	4,806,523	2/21/89	Bentz et al.	514	2	
	2	4,971,952	11/20/90	Bentz et al.	514	12	
	3	5,147,854	9/15/92	Newman	514	12	
	4	5,300,292	4/5/94	Ulich	424	85.2	
	5	5,376,368	12/27/94	Ulich	424	85.2	
	6	5,387,576	2/7/95	Mitrani	514	2	
	7	5,583,103	12/10/96	Ruoslahti et al.	514	8	
	8	5,595,722	1/21/97	Grainger et al.	424	9.2	
	9	5,674,483	10/7/97	Tu et al.	424	85.2	

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
							YES	NO

## OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)

10	Anderson, <i>Nature</i> , 392(supp):25-30 (1998) ✓
11	Atsuta et al., <i>Int. Arch. Allergy Immunol.</i> , 108:31-35 (1995) ✓
12	Aubert et al., <i>Thorax</i> , 49:225-232 (1994)
13	Black et al., <i>Am. J. Physiol.</i> , 271:L910-L917 (1996) ✓
14	Branch, <i>TIBS</i> , 23:45-50 (1998) ✓
15	Broekelmann et al., <i>Proc. Natl. Acad. Sci. USA</i> , 88:6642-6 (1991) ✓
16	Crooke, <i>Antisense Research and Application</i> "Basic Principles of Antisense Therapeutics, Ch. 1, pp. 1-50 (1998) ✓
17	Deguchi, <i>Ann. Rheum. Dis.</i> , 51:362-365 (1992) ✓
18	Denis, <i>Immunology</i> , 82:584-590 (1994) ✓
19	Flanagan et al., <i>Nature Biotechnology</i> , 17:48-52 (1999) ✓
20	Gauldie et al., <i>Ann. N.Y. Acad. Sci.</i> , 796:235-244 (1996) ✓
21	Giri et al., <i>Thorax</i> , 48:959-966 (1993) ✓
22	Goldman, <i>DDT</i> , 2(9):357-358 (1997) ✓
23	Gura, <i>Science</i> , 278:1041-1042 (1997) ✓

RECEIVED

AUG 28 2002

TECH CENTER 1600/2900

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
2879-84SERIAL NO.  
09/945,250INFORMATION DISCLOSURE STATEMENT  
(Use several sheets if necessary)APPLICANT  
IRVINFILING DATE  
August 31, 2001

GROUP ART



24	Jachimczak et al., <i>Int. J. Cancer</i> , <b>65</b> :332-337 (1996) ✓
25	Khalil, et al., <i>Am. J. Physiol.</i> <b>267</b> ( <i>Lung Cell. Mol. Physiol.</i> <b>11</b> ):L498-L507 (1994) /
26	Khalil et al., <i>Am. J. Respir. Cell Mol. Biol.</i> , <b>14</b> :131-138 (1996) /
27	Lawrence, <i>Eur. Cytokine Netw.</i> , <b>7</b> :363-374 (1996) ✓
28	Lloyd, <i>DDT</i> , <b>2</b> (10):397-398 (1997)
29	Martinet et al., <i>Arch. Toxicol. Suppl.</i> , <b>18</b> :127-139 (1996) /
30	Ohno et al., <i>Am. J. Respir. Cell Mol. Biol.</i> , <b>15</b> :404-409 (1996) /
31	Romberger et al., <i>Am. J. Respir. Cell Mol. Biol.</i> , <b>7</b> :149-155 (1992) ✓
32	Stein, <i>Nature Biotechnology</i> , <b>17</b> :751-752 (1999)
33	Uhl et al., <i>Am. J. Respir. Crit. Care Med.</i> , <b>154</b> :1834-1842 (1996) ✓
34	Vignola et al., <i>Clin. Exp. Immunol.</i> , <b>108</b> :114-119 (1996) /
35	Wahl, et al., <i>J. Exp. Med.</i> , <b>177</b> :225-230 (1993) ✓
36	Wangoo et al., <i>J. Clin. Pathol.</i> , <b>48</b> :339-345 (1995) /
37	Wess, <i>DDT</i> , <b>1</b> (12):529-532 (1996) ✓

RECEIVED  
AUG 28 2002  
TECH CENTER 1600/2900

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.